KORU Medical Systems, Inc. announced a development agreement with a biopharmaceutical manufacturer for KORU Medical to develop and seek regulatory approval for a next-generation infusion system for its subcutaneous immunoglobulin (SCIg) therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.13 USD | +0.95% | -3.18% | -13.24% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.24% | 97.48M | |
-7.16% | 178B | |
-4.86% | 67.04B | |
-4.28% | 47.24B | |
+10.32% | 44.62B | |
+8.14% | 42.5B | |
+15.76% | 29.99B | |
+15.53% | 25.22B | |
-5.88% | 24.14B | |
-5.38% | 23.69B |
- Stock Market
- Equities
- KRMD Stock
- News KORU Medical Systems, Inc.
- KORU Medical Systems, Inc. Announces Development Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System